Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Unlike existing treatments that target pathways like glucagon-like peptide 1 (GLP-1), BRP operates through ... to predict cleavage sites in secreted human proteins. The algorithm analyzed ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for ... of cognitive impairment and dementia syndromes. Focusing on evidence from human studies, we highlight how brain energy ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.